Drug profile · INN
troglitazone
REZULIN
troglitazone (REZULIN) is a peroxisome proliferator-activated receptor gamma agonist. Route of administration: oral. Current US regulatory status: approved.
Drug details — troglitazone
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 2
- Programs
- 0
- Data quality
- 0.84
Quick answer
troglitazone (REZULIN) is a peroxisome proliferator-activated receptor gamma agonist. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Peroxisome proliferator-activated receptor gamma agonist
Primary target: Peroxisome proliferator-activated receptor gamma
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Related patents
Frequently asked questions
What is troglitazone?
troglitazone (REZULIN) is a peroxisome proliferator-activated receptor gamma agonist. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for troglitazone?
REZULIN is a marketed brand name for troglitazone. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of troglitazone?
troglitazone has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.